Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study

Table 1 PFS HRs for the ASPIRE ITT population and select subgroups

	At 18 months from randomization	Overall ASPIRE study [25, 36, 46]
	HR (KRd/Rd) (95% CI)
Entire ASPIRE population	0.58 (0.46–0.72)	0.69 (0.57–0.83)
Cytogenetic risk
High^a	0.56 (0.31–0.99)	0.70 (0.43–1.16)
Standard	0.54 (0.37–0.80)	0.66 (0.48–0.90)
Prior lines of treatment
1	0.58 (0.41–0.82)	0.71 (0.53–0.96)
2	0.65 (0.44–0.97)	0.75 (0.54–1.04)
3	0.53 (0.34–0.84)	0.68 (0.47–1.00)
Prior bortezomib treatment	0.59 (0.45–0.78)	0.70 (0.56–0.88)
No prior bortezomib treatment	0.58 (0.39–0.86)	0.73 (0.52–1.02)

CI confidence interval, HR hazard ratio, ITT intent-to-treat, KRd carfilzomib, lenalidomide, and dexamethasone, PFS progression-free survival, Rd lenalidomide and dexamethasone
^aHigh cytogenetic risk was defined by t(4;14), t(14;16), or del(17p) in ≥ 60% of plasma cells. At baseline, 12.1% of KRd-treated patients and 13.1% of Rd-treated patients had high-risk cytogenetics

ISSN: 1756-8722